Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.41 |
| ▸ | CFD | P00746 | 2/20 | 0.35 |
| ▸ | EP300 | Q09472 | 7/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28721684 | 0.82 | F10 (0.44) | F10KLKB1CFDHCRTR1HCRTR2 | |
| SCHEMBL27074546 | 0.77 | KLKB1 (0.53) | F10KLKB1CFDHCRTR1HCRTR2 | |
| SCHEMBL28938019 | 0.76 | KLKB1 (0.54) | F10KLKB1CFDHCRTR1HCRTR2 | |
| SCHEMBL29245880 | 0.74 | HPGD (0.41) | TSHRALDH1A1GLALMNA | |
| SCHEMBL4096033 | 0.73 | F10 (0.47) | F10KLKB1CFDAPOBEC3AAPOBEC3G | |
| SCHEMBL3832110 | 0.72 | F10 (0.60) | F10 | |
| SCHEMBL3828590 | 0.72 | F10 (0.67) | F10 | |
| SCHEMBL3830386 | 0.72 | F10 (0.49) | F10KLKB1 | |
| SCHEMBL24012307 | 0.71 | CYP1A2 (0.49) | F10KLKB1CFDLMNA | |
| SCHEMBL3830392 | 0.71 | F10 (0.58) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108289893-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2022-04-12 | — | — | CN | disclosed |